This work demonstrates the use of a modified mica to concentrate proteins, which is required for proteomic profiling of blood plasma by mass spectrometry (MS). The surface of mica substrates, which are routinely used in atomic force microscopy (AFM), was modified with a photocrosslinker to allow “irreversible” binding of proteins via covalent bond formation. This modified substrate was called the AFM chip. This study aimed to determine the role of the surface and crosslinker in the efficient concentration of various types of proteins in plasma over a wide concentration range. The substrate surface was modified with a 4-benzoylbenzoic acid N-succinimidyl ester (SuccBB) photocrosslinker, activated by UV irradiation. AFM chips were incubated with plasma samples from a healthy volunteer at various dilution ratios (10²X, 10⁴X, and 10⁶X). Control experiments were performed without UV irradiation to evaluate the contribution of physical protein adsorption to the concentration efficiency. AFM imaging confirmed the presence of protein layers on the chip surface after incubation with the samples. MS analysis of different samples indicated that the proteomic profile of the AFM-visualized layers contained common and unique proteins. In the working series of experiments, 228 proteins were identified on the chip surface for all samples, and 21 proteins were not identified in the control series. In the control series, a total of 220 proteins were identified on the chip surface, seven of which were not found in the working series. In plasma samples at various dilution ratios, a total of 146 proteins were identified without the concentration step, while 17 proteins were not detected in the series using AFM chips. The introduction of a concentration step using AFM chips allowed us to identify more proteins than in plasma samples without this step. We found that AFM chips with a modified surface facilitate the efficient concentration of proteins owing to the adsorption factor and the formation of covalent bonds between the proteins and the chip surface. The results of our study can be applied in the development of highly sensitive analytical systems for determining the complete composition of the plasma proteome.

Mass spectrometry (MS) is one of the main techniques for protein identification. Herein, MS has been employed for the identification of bovine serum albumin (BSA), which was covalently immobilized on the surface of a mica chip intended for investigation by atomic force microscopy (AFM). For the immobilization, two different types of crosslinkers have been used: 4-benzoylbenzoic acid N-succinimidyl ester (SuccBB) and dithiobis(succinimidyl propionate) (DSP). According to the data obtained by using an AFM-based molecular detector, the SuccBB crosslinker was more efficient in BSA immobilization than the DSP. The type of crosslinker used for protein capturing has been found to affect the results of MS identification. The results obtained herein can be applied in the development of novel systems intended for the highly sensitive analysis of proteins with molecular detectors.

Early detection of ovarian cancer remains challenging because of the lack of sensitive and reproducible blood-based biomarkers. A major challenge in plasma proteomics is the extremely wide dynamic range of protein concentrations, which prevents simultaneous detection of both high- and low abundance proteins and limits the identification of disease-associated signals. In this study, we applied a combined atomic force microscopy and mass spectrometry (AFM/MS) approach to investigate how sample dilution affects plasma proteome coverage and the detection of differences between healthy donors and patients with stage I and stage III ovarian cancer. Plasma samples were analyzed at two dilution levels (1:100 and 1:10,000). At 1:100 dilution, a total of 235 proteins were identified across all samples, representing the union of all replicates and groups. The reproducible CORE proteome comprised 169 proteins in the Healthy group, 183 in the Stage I group, and 193 in the Stage III group. Differential analysis revealed distinct, non-overlapping protein sets at each dilution level. At 1:100 dilution, most altered proteins were decreased in patients and corresponded to major plasma components, including complement proteins and protease inhibitors. At 1:10,000 dilution, most altered proteins were increased and were predominantly immunoglobulin-related proteins, along with complement regulatory components. These findings show that sample dilution determines which fraction of the plasma proteome is observable. Here, proteome depth refers to the total number of non-redundant proteins accessible within the analytical workflow. When CORE sets from all groups were combined, 216 proteins were identified at 1:100 and 149 at 1:10,000, with 133 shared between the two dilution conditions. The higher dilution contributed 16 additional CORE proteins not detected in the 1:100 CORE union, increasing the combined CORE set to 232 proteins. Thus, higher dilution alone did not increase proteome depth, but provided complementary protein identifications that increased cumulative proteome depth when both dilution conditions were considered together. This effect reflects dilution-dependent selectivity in the composition of the detectable protein subset.